Comparative pharmacogenetics of multiple sclerosis: IFN-β versus glatiramer acetate

Pharmacogenomics

Volumn 15, Issue 5, 2014, Pages 679-685

  Kulakova, Olga G ^a   Tsareva, Ekaterina Yu ^a   Lvovs, Dmitrijs ^b   Favorov, Alexander V ^b,c,d   Boyko, Alexey N ^a   Favorova, Olga O ^a  

^a PIROGOV RUSSIAN NATIONAL RESEARCH MEDICAL UNIVERSITY   (Russian Federation)

^b STATE RESEARCH INSTITUTE OF GENETICS AND SELECTION OF INDUSTRIAL MICROORGANISMS   (Russian Federation)

^c VAVILOV INSTITUTE OF GENERAL GENETICS   (Russian Federation)

^d JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

biomarker; disease modifying treatment; DMT; glatiramer acetate; interferon ; multiple sclerosis; pharmacogenetics; polymorphism

Indexed keywords

BETA INTERFERON; BIOLOGICAL MARKER; GLATIRAMER; IMMUNOSUPPRESSIVE AGENT; PEPTIDE;

ALLELE; CCR5 GENE; CONTROLLED STUDY; CTLA4 GENE; DRB1 GENE; GENE; GENETIC POLYMORPHISM; GENETIC VARIABILITY; HETEROZYGOTE; HUMAN; IFNAR1 GENE; MAJOR CLINICAL STUDY; MULTIPLE SCLEROSIS; PHARMACOGENETICS; REVIEW; TGFB1 GENE; TREATMENT RESPONSE; GENETICS; IMMUNOLOGY; PROCEDURES;

ALLELES; GENES, MHC CLASS II; HETEROZYGOTE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INTERFERON-BETA; MULTIPLE SCLEROSIS; PEPTIDES; PHARMACOGENETICS; POLYMORPHISM, GENETIC;

EID: 84899796817     PISSN: 14622416     EISSN: 17448042     Source Type: Journal    
DOI: 10.2217/pgs.14.26     Document Type: Review

References (29)

1. Rudick RA, Goelz SE. Beta-interferon for multiple sclerosis. Exp. Cell Res. 317(9), 1301-1311 (2011).
2. Johnson KP. Glatiramer acetate for treatment of relapsing-remitting multiple sclerosis. Expert Rev. Neurother. 12(4), 371-384 (2012).
3. Schreiber K, Voldsgaard A, Sorensen PS. Limited effect of interferon-beta for the treatment of secondary progressive multiple sclerosis. Ugeskr. Laeger 175(19), 1342-1344 (2013).
4. Saidha S, Eckstein C, Calabresi PA. New and emerging disease modifying therapies for multiple sclerosis. Ann. NY Acad. Sci. 1247, 117-137 (2012).
5. Mendes A, Sa MJ. Classical immunomodulatory therapy in multiple sclerosis: How it acts, how it works. Arq. Neuropsiquiatr. 69(3), 536-543 (2011).
6. Comi G, Filippi M, Wolinsky JS. European/Canadian multicenter, double-blind, randomized, placebo-controlled study of the effects of glatiramer acetate on magnetic resonance imaging-measured disease activity and burden in patients with relapsing multiple sclerosis. European/Canadian Glatiramer Acetate Study Group. Ann. Neurol. 49(3), 290-297 (2001).
7. Rio J, Nos C, Tintore M. et al. Defining the response to interferon-beta in relapsing-remitting multiple sclerosis patients. Ann. Neurol. 59(2), 344-352 (2006).
8. Gajofatto A, Bacchetti P, Grimes B, High A, Waubant E. Switching first-line disease-modifying therapy after failure: Impact on the course of relapsing-remitting multiple sclerosis. Mult. Scler. 15(1), 50-58 (2009).
9. Foti Cuzzola V, Palella E, Celi D. et al. Pharmacogenomic update on multiple sclerosis: A focus on actual and new therapeutic strategies. Pharmacogenomics J. 12(6), 453-461 (2012).
10. Vandenbroeck K, Comabella M. Single-nucleotide polymorphisms in response to interferon-beta therapy in multiple sclerosis. J. Interferon Cytokine Res. 30(10), 727-732 (2010).
11. Byun E, Caillier SJ, Montalban X. et al. Genome-wide pharmacogenomic analysis of the response to interferon beta therapy in multiple sclerosis. Arch. Neurol. 65(3), 337-344 (2008).
12. Comabella M, Craig DW, Morcillo-Suarez C. et al. Genome-wide scan of 500,000 single-nucleotide polymorphisms among responders and nonresponders to interferon beta therapy in multiple sclerosis. Arch. Neurol. 66(8), 972-978 (2009).
13. Mahurkar S, Suppiah V, O'Doherty C. Pharmacogenomics of interferon beta and glatiramer acetate response: A review of the literature. Autoimmun. Rev. 13(2), 178-186 (2014).
14. Goertsches RH, Zettl UK, Hecker M. Sieving treatment biomarkers from blood gene-expression profiles: A pharmacogenomic update on two types of multiple sclerosis therapy. Pharmacogenomics 12(3), 423-432 (2011).
15. O'Doherty C, Favorov A, Heggarty S. et al. Genetic polymorphisms, their allele combinations and IFN-beta treatment response in Irish multiple sclerosis patients. Pharmacogenomics 10(7), 1177-1186 (2009).
16. Kulakova OG, Tsareva EY, Boyko AN. et al. Allelic combinations of immune-response genes as possible composite markers of IFN-beta efficacy in multiple sclerosis patients. Pharmacogenomics 13(15), 1689-1700 (2012).
17. Tsareva EY, Kulakova OG, Boyko AN. et al. Allelic combinations of immune-response genes associated with glatiramer acetate treatment response in Russian multiple sclerosis patients. Pharmacogenomics 13(1), 43-53 (2012).
18. Tsareva E, Kulakova OG, Makarycheva O. et al. Pharmacogenomics of multiple sclerosis: Association of immune response genes polymorphism with copaxone treatment efficacy. Mol. Biol. (Mosk) 45(6), 963-972 (2011).
19. Polman CH, Reingold SC, Edan G. et al. Diagnostic criteria for multiple sclerosis: 2005 revisions to the 'McDonald Criteria'. Ann. Neurol. 58(6), 840-846 (2005).
20. APSampler software for complex association analysis of genotypic and phenotypic data. https://code.google.com/p/apsampler
21. Favorov AV, Andreewski TV, Sudomoina MA, Favorova OO, Parmigiani G, Ochs MF. A Markov chain Monte Carlo technique for identification of combinations of allelic variants underlying complex diseases in humans. Genetics 171(4), 2113-2121 (2005).
22. Kieseier BC. The mechanism of action of interferon-beta in relapsing multiple sclerosis. CNS Drugs 25(6), 491-502 (2011).
23. Lalive PH, Neuhaus O, Benkhoucha M. et al. Glatiramer acetate in the treatment of multiple sclerosis: Emerging concepts regarding its mechanism of action. CNS Drugs 25(5), 401-414 (2011).
24. He XX, Chang Y, Jiang HJ. et al. Persistent effect of IFNAR-1 genetic polymorphism on the long-Term pathogenesis of chronic HBV infection. Viral Immunol. 23(3), 251-257 (2010).
25. Sudomoina MA, Boiko AN, Demina TL. et al. Connection of multiple sclerosis in the Russian population with alleles of the major histocompatibility complex DRB1 gene. Mol. Biol. (Mosk) 32(2), 291-296 (1998).
26. Ligers A, Teleshova N, Masterman T, Huang WX, Hillert J. CTLA-4 gene expression is influenced by promoter and exon 1 polymorphisms. Genes Immun. 2(3), 145-152 (2001).
27. Sato K, Kawasaki H, Nagayama H. et al. TGF-beta 1 reciprocally controls chemotaxis of human peripheral blood monocyte-derived dendritic cells via chemokine receptors. J. Immunol. 164(5), 2285-2295 (2000).
28. dbSNP: The NCBI curated database of SNPs and other small-scale variants. www.ncbi.nlm.nih.gov/snp
29. NHS curated database of the worldwide allele frequencies. www.allelefrequencies.net